Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - irinotecan hydrochoride-trihydrate -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - irinotecan hydrochloride trihydrate -

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - candesartan cilexetil - tablet - 4 milligram(s) - angiotensin ii antagonists, plain; candesartan

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - candesartan cilexetil - tablet - 16 milligram(s) - angiotensin ii antagonists, plain; candesartan

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - candesartan cilexetil - tablet - 8 milligram(s) - angiotensin ii antagonists, plain; candesartan

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - lidocaine - medicated plaster - 700 milligram(s) - amides; lidocaine

Israel - English - Ministry of Health

novartis israel ltd - pazopanib as hydrochloride - film coated tablets - pazopanib as hydrochloride 200 mg - pazopanib - pazopanib - renal cell carcinoma (rcc)votrient is indicated in adults for the first line treatment of advanced renal cell carcinoma (rcc) and for patients who have received prior cytokine therapy for advanced disease.soft tissue sarcoma (sts)votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (sts) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.

Israel - English - Ministry of Health

novartis israel ltd - pazopanib as hydrochloride - film coated tablets - pazopanib as hydrochloride 400 mg - pazopanib - pazopanib - renal cell carcinoma (rcc)votrient is indicated in adults for the first line treatment of advanced renal cell carcinoma (rcc) and for patients who have received prior cytokine therapy for advanced disease.soft tissue sarcoma (sts)votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (sts) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - pazopanib hydrochloride - tablet - 400mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - pazopanib hydrochloride - tablet - 200mg